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Background: Most women with polycystic ovary syndrome (PCOS) have insulin resistance, hyperinsulinemia, and
elevated serum IL-6 levels. These elevated IL-6 levels may have links with insulin resistance and hyperandrogenism.
Metformin may have beneficial effects on the chronic low-grade inflammatory background associated with PCOS.
Methods: A systematic review was performed via PUBMED, EMBASE, and The Cochrane Library on PCOS studies
published through November 30, 2013. Studies were selected that evaluated the effect of metformin on IL-6 levels
in PCOS patients. Studies not containing adequate diagnosis information about PCOS or not excluding of other
causes of hyperandrogenism were excluded.
Results: Five studies met the inclusion criteria. Of these, one study reported a significant decrease in IL-6 levels after
metformin treatment in women with PCOS. Two studies reported that treatment-related reductions in IL-6 levels
were significantly correlated with insulin metabolism. In the remaining two studies, plasma IL-6 levels did not
change following metformin treatment.
Conclusions: Serum IL-6 levels of PCOS patients may be influenced by metformin. Early application of metformin
therapy may relieve chronic low-grade inflammation in women with PCOS. However, further investigations with
larger samples are needed to better understand the effects of metformin on IL-6 levels and chronic inflammation
in PCOS.
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Polycystic ovary syndrome (PCOS) is the most fre-
quently encountered endocrinopathy and affects 5-8% of
reproductive-age women [1]. It is characterized by chronic
oligo-ovulation or anovulation, clinical or biochemical
hyperandrogenism and polycystic ovaries [2,3]. This
disorder is also associated with an increased risk of
hyperinsulinemia, insulin resistance, type 2 diabetes
mellitus, dyslipidemia, and cardiovascular diseases.
Interleukin-6 (IL-6), a pleiotropic cytokine, plays an
important role in the endocrine system, especially as
related to ovarian maturation and the processes of
fertilization and implantation. IL-6 has also been shown to
modulate ovarian development and function [4].
Therefore, IL-6 may be a key mediator of low-grade
chronic inflammation in PCOS. Moreover, markers of* Correspondence: xuxinghua523@gmail.com
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unless otherwise stated.chronic subclinical inflammation, such as IL-6, have
been shown to be independent risk predictors for the
development of type 2 diabetes [5]. Several studies
have now documented an increase in IL-6 levels in
PCOS patients [6,7]. Both Mohlig et al. and Gonzalez et al.
have pointed out that elevated IL-6 levels may have links
with insulin resistance and hyperandrogenism in PCOS
[5,8]. Taken together, these studies support the hypothesis
that PCOS increases the risk of diabetes by activating
chronic inflammation [5].
More than half of women with PCOS have insulin
resistance and hyperinsulinemia. These insulin abnormal-
ities might play a significant role in the pathogenesis of
PCOS, not only by influencing the reproductive abnormal-
ities of PCOS, but also by amplifying metabolic defects
[9,10]. Hyperinsulinemia may contribute to a hyperandro-
genic state by increasing androgen production of theca
cells and influencing hepatic production of sex hormone
binding globulin, resulting in higher concentrations of freeThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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affected women with reproductive morbidities such as
gestational diabetes mellitus (GDM) and pre-eclampsia,
which are also associated with insulin resistance [10].
Therefore, in PCOS patients, these findings have led to
the development of an important therapeutic strategy
based on insulin-sensitizing drugs, such as metformin.
Metformin has insulin-lowering effects by improving
insulin sensitivity and, in turn, can decrease circulating
androgen levels. In addition, it also plays a critical role
in the treatment of PCOS because women with PCOS
are at an increased risk of insulin resistance [12]. Indeed,
metformin improves insulin-mediated glucose disposal in
women with PCOS [10]. Thus, metformin has become
one of the key drugs in the treatment of PCOS.
Considering the relationship between IL-6 levels and
insulin resistance, metformin has the potential to affect
serum IL-6 levels in PCOS patients. However, literature
about this possible association is scarce and conflicting.
In an attempt to elucidate the effect of metformin on
IL-6 levels, we carried out this systematic review of
the research literature.
Methods
PUBMED, EMBASE, and The Cochrane Library were
searched for articles published up to November 30,
2013, with no bars on foreign languages. The following
key words were used: (PCOS OR polycystic ovary syn-
drome) AND (metformin) AND (interleukin-6 OR IL-6
OR inflammatory cytokine). References from the original
articles found were also analyzed. Studies were included
if they assessed the change of IL-6 levels before and after
taking metformin in patients with PCOS.
Diagnostic criteria were considered valid if they con-
formed to 2003 Rotterdam [13], or 1990 National Insti-
tutes of Health (NIH) criteria [14]. Studies not
containing adequate diagnosis information about PCOS
or not excluding other causes of hyperandrogenism were
ruled out. Case series or reports and reviews were also
excluded.
Results
In total, 76 articles were found. Seventy studies were
ruled out based on their title or abstract. The six
remaining studies evaluated the effect of metformin on
IL-6 levels in PCOS patients. One study was excluded
because it did not meet the objective of the present sys-
tematic review; this study by Ibáñez et al. [15] evaluated
the influence of metformin combined with flutamide to
IL-6 levels (Figure 1).
The five studies that were selected for further analysis
were published between 2004 and 2013, all of them in
English (Table 1). Three included European populations
(Germany, Spain, Poland) [5,16,17] and one studiedwomen of Asia (Taiwan) [6]. The last one study by
Ciaraldi et al. was conducted in America [18]. Information
on the ethnicity of participants was not provided for all
the studies. Patients in these studies did not concurrently
use insulin-sensitizing medication except metformin
before or during the studies.
Sample sizes were varied across studies. Across all of
the five studies, the total number of PCOS women
treated with metformin was 191, and there were 183
control patients. Rotterdam diagnostic criteria were used
in two studies [6,17]; while NIH criteria were used in
one article [18]. The authors of the other two studies
primarily relied on their own criteria; however, these pa-
tients also met the NIH criteria. Basic characteristics of
PCOS patients and controls are presented in Table 1.
Lin and colleagues observed a significant decrease in
IL-6 levels after metformin treatment in PCOS women
(IL-6 level decreased from 28.05 ± 3.26 to 22.04 ±
2.76 pg⁄mL after metformin treatment in PCOS women,
p = 0.0342) [6]. Both Luque-Ramirez et al. [16] and
Ciaraldi et al. [18] suggested that treatment-related reduc-
tions in IL-6 levels were significantly correlated with insu-
lin metabolism. Luque-Ramirez et al. [16] reported that
the decrease in serum IL-6 levels in patients treated with
metformin was inversely correlated with the increase in
the insulin sensitivity index (r = − 0.579, p = 0.048;
intention-to-treat analysis, r = − 0.687, p = 0.001) and
positively correlated with the decrease in the insulin
secretion index (r = 0.577, p = 0.050; intention-to-treat
analysis, r = 0.679, p = 0.001). Ciaraldi et al. [18] also
reported that treatment-related reductions in IL-6 levels
were significantly correlated with drops in fasting insulin
(data was not shown in their article) (Table 2).
Results for the other two studies were inconclusive.
Mohlig et al. [5] reported that IL-6 concentrations did
not change after metformin treatment (34.32 ± 8.28 pg/
ml vs 33.36 ± 8.28 pg/ml, p > 0.05). Jakubowska et al.
[17] was to the only study to focus on a sample of obese
women with PCOS. While there was a significant de-
crease in BMI (35.32 ± 5.07 kg/m2 vs. 33.49 ± 4.80 kg/
m2, p = 0.00002) and waist circumference (106.84 ±
12.69 cm vs. 101.80 ± 11.75 cm, p = 0.005) before and
after metformin treatment, the change in pre-to-post IL-
6 concentrations was not significant (1.72 ± 0.30 pg/ml
vs. 1.91 ± 0.31 pg/ml, p = 0.515) (Table 2).
Across all five studies, there was substantial variation
in drug dosage, route of administration of metformin,
patient BMI, and patient levels of insulin metabolism be-
fore metformin treatment. As such, a true meta-analysis
was not performed across all of these variables because
such analysis would not have yielded clinically meaning-
ful results. Thus, the body of evidence was not consist-
ent or strong and ore empirical research is needed in
this area.
Figure 1 Flow chart of literature review.
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As a complex and heterogeneous disorder, the pathogenesis
of PCOS has remained largely unknown until now. Over
the past few decades, PCOS researchers have focused their
attention on the state of chronic low-grade subclinical
inflammation and how it relates to the endocrine, meta-
bolic, and reproductive disturbances in PCOS patients.
Genetic variants in the genes encoding inflammation-
related mediators underlie the development of PCOS and
their interaction with environmental factors may contribute
to the heterogeneous clinical phenotypes of PCOS [19].
Insulin resistance has been increasingly recognized as
having an important role in inflammatory pathways [9],
and metformin may play an important role in improving
low-grade inflammation in PCOS. Hence, the present study
systematically reviewed the empirical research literature
relating metformin to serum IL-6 levels in PCOS.
With regard to young and lean PCOS patients,
elevated IL-6 levels have been observed to decrease after
metformin treatment. Lin et al. demonstrated that IL-6may be an early low-grade chronic inflammatory marker
in PCOS [6], a finding that is consistent with other
evidence that IL-6 may be a key mediator of low-grade
chronic inflammation in PCOS [4]. This research on IL-6
is shedding further light on the pathogenesis of PCOS and
the long-term cardiovascular disease risk associated
with PCOS [20]. Therefore, strategies ameliorating
inflammation may be useful for the management of
PCOS and associated conditions [19].
Modern chronic drug treatment for PCOS patients is
typically based on the administration of oral contraceptives,
antiandrogens, and/or insulin sensitizers [16]. As a biguan-
ide that improves insulin sensitivity, metformin has been
extensively evaluated in PCOS [11] and has been shown to
play a critical role in improving low-grade inflammation in
PCOS [9]. Lin et al. found there was a significant decrease
in IL-6 levels after metformin treatment in PCOS women
[6]. Luque-Ramirez et al. confirmed that metformin may
have beneficial effects on the inflammatory background
associated with PCOS [16]. Ciaraldi et al. indicated that
Table 1 Basic characteristics of PCOS patients and controls










Control PCOS P Control PCOS P
Mohlig et al. 2004 [5] clinical symptoms and on
laboratory findings*
European Germany 30.5 ± 1.5 28.9 ± 0.7 0.33 26.0 ± 1.3 30.3 ± 1.0 0.037 Fasting glucose Fasting
insulin
Jakubowska et al. 2008 [17] 2003 Rotterdam criteria European Poland 31.55 ± 7.36 28.24 ± 6.27 >0.05 32.94 ± 6.13 35.32 ± 5.07 >0.05 NON Fasting
insulin
Luque-Ramirez et al. 2010 [16] hyperandrogenism, ovulatory
dysfunction and exclusion of
secondary etiologies
European Spain 27 ± 5 24 ± 6 0.138 29 ± 8 30 ± 6 0.674 AUC glucose NON
Lin et al. 2011 [6] 2003 Rotterdam Asia China, Taiwan 31.92 ± 0.58 27.67 ± 0.45 <0.0001 22.11 ± 0.45 24.25 ± 0.51 0.0025 PC sugar 2-hr insulin
Ciaraldi et al. 2013 [18] 1990 NIH America USA 32 ± 1 28 ± 1 <0.05 39.4 ± 2.2 35.6 ± 1.5 >0.05 2 h glucose NON
AUC: area under the curve of the oral glucose tolerance test; NON: no difference was reported.






















Table 2 Characteristics of studies evaluating effect of metformin on IL-6 levels of polycystic ovary syndrome
Author and year
of publication







Mohlig et al. 2004 [5] 9 obese, insulin-resistant
PCOS patients
20 health women 850 mg, three times
daily, 6 months
1.72 ± 0.30 1.91 ± 0.31 0.515 After 6 months therapy, IL-6
concentrations remained
largely unchanged




500 mg, twice daily,
6 months
34.32 ± 8.28 33.36 ± 8.28 >0.05 plasma IL-6 levels did not
change during therapy
Luque-Ramirez et al. 2010 [16] 19 PCOS women 18 health women 850 mg, twice daily,
24 weeks
1.0 ± 0.9 0.7 ± 0.5 0.56 The decrease observed in
serum IL-6 levels in the
patients treated with
metformin correlated
inversely with the increase
in the insulin sensitivity
index and directly with
the decrease in the insulin
secretion index
Lin et al. 2011 [6] 129 PCOS women 109 control women 500 mg, three times
daily, 12 weeks
28.05 ± 3.26 22.04 ± 2.76 0.0342 There was a significant
decrease in IL-6 level after
metformin treatment in
PCOS women.
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cantly correlated with drops in fasting insulin levels [18].
However, Mohlig et al. and Jakubowska et al. failed to find
any changes of plasma IL-6 levels with metformin therapy
in PCOS patients [5,17]. Thus, considering the fact that
PCOS is a very heterogeneous disease, it is difficult to study
the exact influence of metformin on the inflammation
state of PCOS women. In order to reduce the influence of
heterogeneity, studies between different subgroups are
required. Nevertheless, the number of relevant studies
reviewed here are limited and they did not carry out
analyses of different PCOS subgroups. Ignoring the
heterogeneity of PCOS is perhaps one of the reason why
discrepant results have been reported in the literature.
Obesity is frequently present in women with PCOS.
Continuous release of inflammatory mediators such as
IL-6 perpetuates the inflammatory condition associated
with obesity in PCOS, possibly contributing to insulin
resistance and other long-term cardiometabolic risk
factors [19]. Linear regression models have revealed
that BMI is the dominant parameter determining IL-6
and C-reactive protein (CRP) values in PCOS [5].
Gözdemir et al. suggested that obesity was the principle
mechanism of chronic inflammation and insulin resistance
in PCOS patients. CRP and IL-6 should be used to predict
and follow the risk of CVD development in PCOS cases
[21]. However, six months of metformin therapy with
obese PCOS women in the study of Jakubowska et al. were
insufficient to reliably decrease their IL-6 levels [17]. BMI
and fat mass may improve while elevated IL-6 levels are
maintained [5]. Among the other studies included in this
systematic review, calculations for determining the
relationship between BMI and IL-6 were not explicitly
made [6,16,18], so further investigations are needed to
address these interrelationships.
Another possible reason for the mixed results across
the literature regarding the influence of metformin on
the level of IL-6 could be ethnic and geographic
variation. Discrepancies could also be explained by the
small sample size of some included studies, which may
result in substantial errors from estimation. In view of the
current data, most sample sizes are small [5,16-18]. Only
the study of Lin et al. involved a large sample with
129 PCOS women and 109 controls [6]. Population
stratification and sample size are important issues to
be concerned in human surveys.
Despite on the above considerations, we endorse
that metformin does seem to significantly influence
IL-6 levels. PCOS women with early application of
metformin therapy may improve their state of chronic
inflammation. However, the literature shows conflict-
ing results because of different study designs. Future
studies with diverse populations are needed with
larger samples to better understand the effect ofmetformin on IL-6 levels and chronic inflammation of
PCOS women.
Conclusions
In the present study, the relationship between the IL-6
levels and metformin in PCOS was systematically reviewed.
Across several studies, the data support that metformin
may influence IL-6 levels and ameliorate the state of
chronic inflammation in PCOS women that receive early
metformin therapy. Considering the conflicting results
reported in the literature, however, further investigations
are necessary with larger samples to understand
better the effect of metformin on the IL-6 levels and
chronic inflammation in PCOS.
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